Congressional Research Service Reports - 388 Matching Results
Search Results
- Medicare: Prescription Drug Proposals
- This report provides an overview of the President’s plan and the legislation introduced to date in the 106th Congress. It
- Medicare: Selected Prescription Drug Proposals
- Report on selected prescription drug proposals in the Medicare program, including a cost benefits analysis, summary of proposals, background of the issues, and more.
- Medicare: Side-by-Side Comparison of Selected Prescription Drug Bills
- Report comparing prescription drug bills in the Medicare program, including an examination of the covered population, benefits, deductibles, premiums, and more.
- Medicare: Beneficiary Cost-Sharing Under Prescription Drug Legislation
- This report provides an analysis of how the cost-sharing and premium provisions under the Prescription Drug and Medicare Improvement Act of 2003 (S. 1) and the Medicare Prescription Drug and Modernization Act of 2003 (H bill would affect the amount that a beneficiary would pay annually for prescription drugs.
- Medicare: Beneficiary Cost-Sharing Under Proposed Prescription Drug Benefits
- This report examines these proposals as well as the “Medicare Rx Drug Benefit and Discount Act of 2003,” which was introduced by Representative Charles Rangel, the ranking member of the House Ways and Means Committee. Specifically, this report provides background on how the cost-sharing and premium provisions under each bill would affect the amount that a beneficiary pays annually for prescription drugs.
- Medicare: Beneficiary Cost-Sharing Under Proposed Prescription Drug Benefits
- This report provides background on how the cost-sharing and premium provisions under each bill would affect the amount that a beneficiary pays annually for prescription drugs. In addition, this report gives examples of how annual cost-sharing would differ for beneficiaries with various levels of total prescription drug spending in 2006 under the plans.
- Medicare Prescription Drug and Reform Legislation
- This report describes the major features of S. 1, as ordered reported, and the measure to be considered by the House Ways and Means Committee, H.R. 2473, as ordered reported.
- Overview of the Medicare Prescription Drug and Reform Legislation
- No Description Available.
- Overview of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003
- No Description Available.
- Medicare Prescription Drug Provisions of S.1, as Passed by the Senate, and H.R. 1, as Passed by the House
- This report discusses differences in the specifics of the prescription drug provisions in S. 1 and H.R. 1 and provides a side-by-side comparison of the Title I provisions of both bills.
- Medicare's Skilled Nursing Facility Benefit
- No Description Available.
- Tobacco Price Support: An Overview of the Program
- No Description Available.
- Federal R&D, Drug Discovery, and Pricing: Insights from the NIH-University-Industry Relationship
- Interest in methods to provide drugs at lower cost, particularly for the elderly, has rekindled discussion over the role the federal government plays in facilitating the creation of new pharmaceuticals for the marketplace. This report explores the issue of whether or not the substantial federal investment in health-related research and development (R&D) entitles the public to commensurate consideration in prices charged for any resulting drugs. It is intended to provide the reader with an understanding of the rationale for government support of R&D and subsequent efforts to facilitate private sector commercialization of new technologies generated from such work. Concerns surrounding innovation in pharmaceuticals and biotechnology are discussed within the broader context of the federal role in facilitating technological progress.
- Medical Records Privacy: Questions and Answers on the HIPAA Final Rule
- This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
- Medical Records Privacy: Questions and Answers on the HIPAA Final Rule
- This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
- Medical Records Privacy: Questions and Answers on the HIPAA Final Rule
- This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
- Medical Records Privacy: Questions and Answers on the HIPAA Final Rule
- This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
- Medical Records Privacy: Questions and Answers on the HIPAA Final Rule
- This report discusses the issue facing Congress on whether to continue to support the executive branch’s prosecution of medical marijuana patients and their providers, in accordance with marijuana’s status as a Schedule I drug under the Controlled Substances Act, or whether to relax federal marijuana prohibition enough to permit the medical use of botanical cannabis products by seriously ill persons, especially in states that have created medical marijuana programs under state law.
- The Hatch-Waxman Act: Proposed Legislative Changes
- No Description Available.
- The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
- This record provides information about The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents. Congressional interests in the cost of Pharmaceuticals have focused attention on several areas where the federal government has policies and programs.
- The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
- This record provides information about The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents. Congressional interests in the cost of Pharmaceuticals have focused attention on several areas where the federal government has policies and programs.
- The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
- This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on the Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
- The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
- This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
- The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
- This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
- The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
- This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
- The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
- This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
- The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
- This report describes the Proposed Legislative Changes Affecting Pharmaceutical Patents on Hatch-Waxman Act. The Hatch-Waxman Act provides the FDA with certain authorities to offer periods of marketing for a pharmaceutical independent of the rights conferred by patents.
- The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents
- This record provides information about The Hatch-Waxman Act: Proposed Legislative Changes Affecting Pharmaceutical Patents. Congressional interests in the cost of Pharmaceuticals have focused attention on several areas where the federal government has policies and programs.
- The Cost of Prescription Drugs for the Uninsured Elderly and Legislative Approaches
- The purpose of this report is to explain why many of those who are least able to afford high drug costs are those who are most frequently charged the most. This report describes the basic economic theory underlying price differentiation and, in the context of the pharmaceutical market, analyzes the role and behavior of pharmacy benefit managers (PBMs), pharmaceutical manufacturers, and retail pharmacies, respectively. It also looks at a number of the criticisms that have been made of the practice of differential pricing. Finally, this report discusses various policy approaches aimed at assisting the elderly to purchase prescription drugs.
- President Bush's Proposed Medicare-Endorsed Drug Discount Card Initiative: Status and Issues
- No Description Available.
- President Bush's Proposed Medicare-Endorsed Drug Discount Card Initiative: Status and Issues
- No Description Available.
- President Bush's Proposed Medicare-Endorsed Drug Discount Card Initiative: Status and Issues
- No Description Available.
- Medicare: Major Prescription Drug Provisions of Selected Bills
- No Description Available.
- Medicare: Major Prescription Drug Provisions of Selected Bills
- No Description Available.
- Medicare: Major Prescription Drug Provisions of Selected Bills
- No Description Available.
- Importing Prescription Drugs
- No Description Available.
- Importing Prescription Drugs
- No Description Available.
- Prescription Drug Importation and Internet Sales: A Legal Overview
- No Description Available.
- Importing Prescription Drugs: Objectives, Options, and Outlook
- No Description Available.
- Prescription Drugs: Importation for Personal Use
- No Description Available.
- Ecstasy: Actions of the 107th Congress to Control MDMA
- Legislation has been proposed in the 107th Congress to combat the use and abuse of Ecstasy (MDMA) and other “club drugs.” In a 2001 survey, 12% of 12th graders reported ever having taken the drug. The Ecstasy Anti-Proliferation Act of 2000, enacted by the 106th Congress, directed the U.S. Sentencing Commission to increase penalties for Ecstasy offenses. As of March 2001, MDMA penalties became more severe than for powder cocaine but less severe than for heroin.
- Ecstasy: Actions of the 107th Congress to Control MDMA
- Legislation has been proposed in the 107th Congress to combat the use and abuse of Ecstasy (MDMA) and other “club drugs.” In a 2001 survey, 12% of 12th graders reported ever having taken the drug. The Ecstasy Anti-Proliferation Act of 2000, enacted by the 106th Congress, directed the U.S. Sentencing Commission to increase penalties for Ecstasy offenses. As of March 2001, MDMA penalties became more severe than for powder cocaine but less severe than for heroin.
- Ecstasy: Actions of the 107th Congress to Control MDMA
- Legislation has been proposed in the 107th Congress to combat the use and abuse of Ecstasy (MDMA) and other “club drugs.” In a 2001 survey, 12% of 12th graders reported ever having taken the drug. The Ecstasy Anti-Proliferation Act of 2000, enacted by the 106th Congress, directed the U.S. Sentencing Commission to increase penalties for Ecstasy offenses. As of March 2001, MDMA penalties became more severe than for powder cocaine but less severe than for heroin.
- Ecstasy: Legislative Proposals in the 107th Congress to Control MDMA
- Legislation has been proposed in the 107th Congress to combat the use and abuse of Ecstasy (MDMA) and other “club drugs.” In a 2001 survey, 12% of 12th graders reported ever having taken the drug. The Ecstasy Anti-Proliferation Act of 2000, enacted by the 106th Congress, directed the U.S. Sentencing Commission to increase penalties for Ecstasy offenses. As of March 2001, MDMA penalties became more severe than for powder cocaine but less severe than for heroin.
- Legal Issues Related to Prescription Drug Sales on the Internet
- No Description Available.
- Abortion Services and Military Medical Facilities
- The purpose of this report is to describe and discuss the provisions for providing abortion services to military personnel, their dependents and other military health care beneficiaries at military medical facilities. The report describes the history of these provisions, with particular emphasis on legislative actions. Finally, this report discusses a number of proposals to modify the Clinton Administration provisions, as well as recently enacted legislation.
- Abortion Services and Military Medical Facilities
- The purpose of this report is to describe and discuss the provisions for providing abortion services to military personnel, their dependents and other military health care beneficiaries at military medical facilities. The report describes the history of these provisions, with particular emphasis on legislative actions. Finally, this report discusses a number of proposals to modify the Clinton Administration provisions, as well as recently enacted legislation.
- Military Medical Care Services: Questions and Answers
- No Description Available.
- Military Medical Care Services: Questions and Answers
- No Description Available.
- Military Medical Care Services: Questions and Answers
- No Description Available.